<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.
Where this comes from
- Record sourced from PubMed, PMID 38991179.
- Also identified by DOI 10.1200/PO.23.00215.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Aniline Compounds
- Acrylamides
- Lung Neoplasms
- ErbB Receptors